US Patent Issued to Hangzhou Highlightll Pharmaceutical on Feb. 17 for "JAK1 selective inhibitors and uses thereof" (Florida Inventor)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. RE50,799, issued on Feb. 17, was assigned to Hangzhou Highlightll Pharmaceutical Co. Ltd (Iselin, N.J.).

"JAK1 selective inhibitors and uses thereof" was invented by Congxin Liang (Palm Beach Gardens, Fla.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The new 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives are selective Jak1 kinase inhibitors useful in treating disorders related to Jak1 activities such as autoimmune diseases or disorders, inflammatory diseases or disorders, and cancer or neoplastic diseases or disorders."

The patent was filed on March 16, 2023, under Application No. 18/122,295.

*For further information, including images, charts and tab...